DBTX · Decibel Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.83M | $7.93M | - | $10.03M | $11.24M | $7.47M | - | $4.69M | $5.30M | $7.44M |
| SG&A | $6.21M | $6.19M | - | $6.32M | $5.86M | $6.55M | - | $5.68M | $2.56M | $4.18M |
| Total Operating Expenses | $19.04M | $14.12M | - | $16.35M | $17.10M | $14.02M | - | $14.70M | $11.73M | $11.61M |
| D&A | - | $340.0K | - | - | - | $367.0K | - | - | - | $487.0K |
| Operating Income | ($19.04M) | ($14.12M) | - | ($16.35M) | ($17.10M) | ($14.02M) | - | ($14.70M) | ($11.73M) | ($11.61M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $80.0K | $61.0K | - | $30.0K | $38.0K | $60.0K | - | $0 | - | - |
| Net Income | ($18.14M) | ($13.30M) | - | ($16.00M) | ($17.05M) | ($14.02M) | - | ($16.40M) | ($7.81M) | ($11.54M) |
| EPS - Basic | ($0.68) | ($0.53) | - | ($0.66) | - | - | - | - | - | - |
| EPS - Diluted | ($0.68) | ($0.53) | - | ($0.64) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.80M | $38.06M | $34.61M | $36.68M | $56.45M | $10.78M | $36.45M | $51.41M | $12.37M | $52.24M |
| Accounts Receivable | $0 | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $617.0K | $1.28M | $1.06M | $3.03M | $1.92M | $1.21M | $4.01M | $1.81M | $2.14M | $1.00M |
| Current Assets | $80.45M | $95.87M | $108.03M | $126.29M | $141.41M | $151.24M | $164.19M | $149.87M | $161.30M | $57.83M |
| Total Assets | $94.39M | $110.45M | $123.37M | $142.27M | $158.28M | $173.78M | $184.48M | $185.29M | $196.90M | $67.28M |
| Current Liabilities | $26.58M | $23.18M | $22.44M | $23.37M | $22.87M | $18.11M | $20.54M | $16.50M | $16.64M | $15.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $41.08M | $40.61M | $41.58M | $45.46M | $46.42M | $45.66M | $42.79M | $31.13M | $27.48M | $28.98M |
| Stockholders' Equity | $53.31M | $69.84M | $81.79M | $96.81M | $111.86M | $128.12M | $141.69M | ($147.64M) | $169.41M | $180.27M |
| Retained Earnings | ($308.97M) | ($290.82M) | ($277.52M) | ($261.58M) | ($245.57M) | ($228.53M) | ($214.51M) | ($201.61M) | ($185.21M) | ($162.69M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($17.06M) | - | - | - | ($22.01M) | - | - | - | ($11.91M) |
| Investing Cash Flow | - | $20.32M | - | - | - | ($3.62M) | - | - | - | $11.69M |
| Financing Cash Flow | - | $197.0K | - | - | - | ($52.0K) | - | - | - | $153.15M |
| CapEx | - | $266.0K | - | - | - | $101.0K | - | - | - | $56.0K |
| Free Cash Flow | - | ($17.32M) | - | - | - | ($22.11M) | - | - | - | ($11.96M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 1.30 | - | - | - | 1.58 | - | - | - | 1.04 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.2% | -12.0% | - | -11.2% | -10.8% | -8.1% | - | -8.9% | -4.0% | -17.1% |
| Return on equity | -34.0% | -19.0% | - | -16.5% | -15.2% | -10.9% | - | 11.1% | -4.6% | -6.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.03 | 4.14 | 4.81 | 5.40 | 6.18 | 8.35 | 7.99 | 9.08 | 9.70 | 3.81 |
| Quick ratio | 3.03 | 4.14 | 4.81 | 5.40 | 6.18 | 8.35 | 7.99 | 9.08 | 9.70 | 3.81 |
| Cash ratio | 1.50 | 1.64 | 1.54 | 1.57 | 2.47 | 0.60 | 1.78 | 3.12 | 0.74 | 3.44 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.77 | 1.58 | 1.51 | 1.47 | 1.41 | 1.36 | 1.30 | -1.26 | 1.16 | 0.37 |
| Liabilities / Assets | 0.44 | 0.37 | 0.34 | 0.32 | 0.29 | 0.26 | 0.23 | 0.17 | 0.14 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.3% | -0.7% | - | -11.2% | -45.9% | -20.7% | - | - | - | - |
| Net income growth (YoY) | -6.4% | 5.1% | - | 2.4% | -118.3% | -21.5% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 21.6% | - | - | - | -84.8% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -52.3% | -45.5% | -42.3% | - | -34.0% | -28.9% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Decibel Therapeutics against the 5 most active filers in the same SIC group.